Eye Care
Treatment for Wet Age-Related Macular Degeneration Receives Biologics License Application Approval
Treatment for Wet Age-Related Macular Degeneration Receives Biologics License Application Approval
Estimates suggest that by 2020, 1.5 to 1.75 million people in the U.S. will be living with wet AMD, a leading cause of blindness worldwide and a rapidly growing public health concern, according to Novartis.
Read More >>
FDA OKs Acyclovir Ophthalmic Ointment
New Ophthalmic Gel Receives FDA Approval For Postoperative Ocular Treatment
Task Force Recommends Ocular Prophylaxis for Gonococcal Ophthalmia Neonatorum
FDA Officials OK Dextenza for Post-Ophthalmic Surgery Pain Management
This Halloween, Discuss Potential Dangers of Costume Contacts
FDA Approves First Drug for Neurotrophic Keratitis
CDC: Poor Contact Lens Hygiene Increases Risk of Infection
View more articles >>
Clinical Trials
STudy to Assess Rapid Disease Progression by Clinical and Genetic Factors In Glaucoma patientS That Are High Risk
Diagnostic Innovations in Glaucoma Study
Evaluation of the XEN Implant in Moderate Primary Open Angle Glaucoma (POAG) Participants
Effects of Prostaglandin Analogue Washout Following Long-term Therapy in Adults With Primary Open Angle Glaucoma
Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied
Multimedia: Videos
Research to Cure Vision and Brain Disorders
Research to Cure Vision and Brain Disorders
Glaucoma Treatments
Glaucoma Treatments
Glaucoma Overview
Glaucoma Overview